Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
3.860
+0.130 (3.49%)
At close: Sep 11, 2026, 4:00 PM EDT
3.850
-0.010 (-0.26%)
After-hours: Sep 11, 2026, 4:10 PM EDT
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $5.00K in the quarter ending June 30, 2026, a decrease of -99.72%. This brings the company's revenue in the last twelve months to $4.70M, up 12.79% year-over-year. In the year 2025, Bolt Biotherapeutics had annual revenue of $7.70M with 0.07% growth.
Revenue (ttm)
$4.70M
Revenue Growth
+12.79%
P/S Ratio
1.53
Revenue / Employee
$204,348
Employees
23
Market Cap
7.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 5.00K | 0.07% |
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | 215.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.73M |
| Evogene | 1.66M |
| CollPlant Biotechnologies | 389.00K |
| Lexaria Bioscience | 194.00K |
| AIM ImmunoTech | 95.00K |
| Soligenix | 2.34K |
| Ernexa Therapeutics | 1.00K |
BOLT News
- 4 weeks ago - Bolt Biotherapeutics reports Q2 EPS ($4.57) vs. ($4.46) last year - TheFly
- 4 weeks ago - Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Bolt Biotherapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Bolt Biotherapeutics Quarterly report: Q2 2026 - Filings
- 3 months ago - Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project - Accesswire
- 3 months ago - Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 4 months ago - Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Quarterly report: Q1 2026 - Filings